JPWO2020123773A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020123773A5 JPWO2020123773A5 JP2021533524A JP2021533524A JPWO2020123773A5 JP WO2020123773 A5 JPWO2020123773 A5 JP WO2020123773A5 JP 2021533524 A JP2021533524 A JP 2021533524A JP 2021533524 A JP2021533524 A JP 2021533524A JP WO2020123773 A5 JPWO2020123773 A5 JP WO2020123773A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- orf1
- acid sequence
- synthetic
- orf2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 83
- 108020004707 nucleic acids Proteins 0.000 claims description 52
- 102000039446 nucleic acids Human genes 0.000 claims description 52
- 239000002245 particle Substances 0.000 claims description 42
- 230000002068 genetic effect Effects 0.000 claims description 41
- 101000833492 Homo sapiens Jouberin Proteins 0.000 claims description 35
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 claims description 35
- 102100024407 Jouberin Human genes 0.000 claims description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 29
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 claims description 29
- 101710130262 Probable Vpr-like protein Proteins 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 101150097234 ORF2/3 gene Proteins 0.000 claims description 14
- 101100028137 Torque teno virus (isolate Human/Finland/Hel32/2002) ORF1/1 gene Proteins 0.000 claims description 14
- 101100028140 Torque teno virus (isolate Human/Finland/Hel32/2002) ORF1/2 gene Proteins 0.000 claims description 14
- 239000012636 effector Substances 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000011541 reaction mixture Substances 0.000 claims description 10
- 241001339993 Anelloviridae Species 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 7
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 6
- 108020004638 Circular DNA Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims description 2
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- -1 TAIP Proteins 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000004074 complement inhibitor Substances 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims description 2
- 102000003675 cytokine receptors Human genes 0.000 claims description 2
- 108010057085 cytokine receptors Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 238000000424 optical density measurement Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 230000000295 complement effect Effects 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 2
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 claims 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024083619A JP2024100936A (ja) | 2018-12-12 | 2024-05-22 | 分泌治療モダリティを送達するためのアネロソーム |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778866P | 2018-12-12 | 2018-12-12 | |
| US201862778869P | 2018-12-12 | 2018-12-12 | |
| US62/778,869 | 2018-12-12 | ||
| US62/778,866 | 2018-12-12 | ||
| PCT/US2019/065919 WO2020123773A2 (en) | 2018-12-12 | 2019-12-12 | Anellosomes for delivering secreted therapeutic modalities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083619A Division JP2024100936A (ja) | 2018-12-12 | 2024-05-22 | 分泌治療モダリティを送達するためのアネロソーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512395A JP2022512395A (ja) | 2022-02-03 |
| JP2022512395A5 JP2022512395A5 (https=) | 2022-12-20 |
| JPWO2020123773A5 true JPWO2020123773A5 (https=) | 2022-12-20 |
Family
ID=69160343
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533524A Pending JP2022512395A (ja) | 2018-12-12 | 2019-12-12 | 分泌治療モダリティを送達するためのアネロソーム |
| JP2024083619A Pending JP2024100936A (ja) | 2018-12-12 | 2024-05-22 | 分泌治療モダリティを送達するためのアネロソーム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083619A Pending JP2024100936A (ja) | 2018-12-12 | 2024-05-22 | 分泌治療モダリティを送達するためのアネロソーム |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230048858A1 (https=) |
| EP (1) | EP3894568A2 (https=) |
| JP (2) | JP2022512395A (https=) |
| KR (1) | KR20210131309A (https=) |
| CN (1) | CN113631717A (https=) |
| AU (1) | AU2019396520A1 (https=) |
| BR (1) | BR112021009379A2 (https=) |
| CA (1) | CA3119531A1 (https=) |
| IL (1) | IL283778A (https=) |
| MX (1) | MX2021006943A (https=) |
| WO (1) | WO2020123773A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11624061B2 (en) | 2017-04-28 | 2023-04-11 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| BR112020005803A2 (pt) | 2017-09-25 | 2020-12-01 | Agrospheres, Inc. | composições e métodos para produção e administração moduláveis de produtos biológicos |
| BR112021011124A2 (pt) * | 2018-12-12 | 2022-03-15 | Flagship Pioneering Innovations V Inc | Anelossomos e métodos de uso |
| JP2022513459A (ja) * | 2018-12-12 | 2022-02-08 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | タンパク質代替治療モダリティを送達するためのアネロソーム |
| JP2023530451A (ja) * | 2020-06-17 | 2023-07-18 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | アネロウイルスを同定し及び特徴付ける方法並びにその使用 |
| JP2023548838A (ja) * | 2020-10-29 | 2023-11-21 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | ニワトリ貧血ウイルス（ｃａｖ）に基づくベクター |
| KR20230146560A (ko) * | 2021-02-08 | 2023-10-19 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 하이브리드 aav-아넬로벡터 |
| WO2022241013A1 (en) * | 2021-05-12 | 2022-11-17 | Flagship Pioneering Innovations V, Inc. | Anellovectors and methods of use |
| CN118284411A (zh) * | 2021-10-12 | 2024-07-02 | 旗舰先锋创新V股份有限公司 | 新颖的指环载体组合物和方法 |
| EP4415695A4 (en) * | 2021-10-12 | 2025-11-26 | Flagship Pioneering Innovations V Inc | NEW ANELLOVECTOR COMPOSITIONS AND METHODS |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| TW202529819A (zh) | 2023-10-13 | 2025-08-01 | 美商旗艦先鋒創新公司 | 組織特異性指環載體(anellovector)遞送 |
| CN117695410B (zh) * | 2024-02-06 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | CRISPR/Cas9纳米抗菌剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395472B1 (en) * | 1999-02-05 | 2002-05-28 | Abbott Laboratories | Methods of utilizing the TT virus |
| AU2014361781B2 (en) * | 2013-12-12 | 2021-04-01 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing |
| CN108291216B (zh) * | 2015-09-24 | 2022-09-16 | 宾夕法尼亚州大学信托人 | 用于治疗补体介导的疾病的组合物和方法 |
| IL271275B1 (en) * | 2017-06-13 | 2026-04-01 | Flagship Pioneering Innovations V Inc | Preparations containing croons and their uses |
| BR112020007405A2 (pt) * | 2017-10-18 | 2020-12-08 | Regenxbio Inc. | Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos |
-
2019
- 2019-12-12 KR KR1020217021775A patent/KR20210131309A/ko active Pending
- 2019-12-12 CN CN201980091251.6A patent/CN113631717A/zh active Pending
- 2019-12-12 AU AU2019396520A patent/AU2019396520A1/en active Pending
- 2019-12-12 MX MX2021006943A patent/MX2021006943A/es unknown
- 2019-12-12 EP EP19836323.6A patent/EP3894568A2/en active Pending
- 2019-12-12 US US17/413,207 patent/US20230048858A1/en not_active Abandoned
- 2019-12-12 CA CA3119531A patent/CA3119531A1/en active Pending
- 2019-12-12 JP JP2021533524A patent/JP2022512395A/ja active Pending
- 2019-12-12 WO PCT/US2019/065919 patent/WO2020123773A2/en not_active Ceased
- 2019-12-12 BR BR112021009379-6A patent/BR112021009379A2/pt unknown
-
2021
- 2021-06-07 IL IL283778A patent/IL283778A/en unknown
-
2024
- 2024-05-22 JP JP2024083619A patent/JP2024100936A/ja active Pending
-
2025
- 2025-06-17 US US19/240,368 patent/US20260009050A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114736901B (zh) | 用于减少pd-l1表达的寡核苷酸 | |
| JPWO2020123773A5 (https=) | ||
| JP2019014733A (ja) | Ｔｎｆスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用 | |
| WO1986007609A1 (fr) | VECTEUR D'EXPRESSION DE L'INTERFERON-gamma DANS LES CELLULES DE MAMMIFERE, PROCEDE POUR SA MISE EN OEUVRE, PRODUIT OBTENU ET COMPOSITION PHARMACEUTIQUE CONTENANT L'INTERFERON-gamma | |
| CN114941011B (zh) | 慢病毒载体及其应用 | |
| JP7737385B2 (ja) | 遺伝子療法のためのａａｖ２をベースとするウイルスベクター粒子 | |
| CN113249380B (zh) | 靶向covid-19新冠病毒的反义寡核苷酸、natac嵌合分子及其应用 | |
| TW202239762A (zh) | 桿狀病毒表現系統 | |
| JPWO2020123795A5 (https=) | ||
| CN114934070A (zh) | 间充质干细胞及其抗炎应用 | |
| JPWO2020123816A5 (https=) | ||
| CN106167791B (zh) | MSC-TNF α-AB干细胞及其制备方法和应用 | |
| JPWO2020123753A5 (https=) | ||
| WO2019091457A1 (zh) | 肝脏特异性转录调控序列及其应用 | |
| KR20230124682A (ko) | Rna를 봉입하는 아넬로바이러스 캡시드의 시험관 내어셈블리 | |
| US20170253879A1 (en) | APTAMER-RNAi THERAPEUTIC COMPOSITIONS | |
| CN110079553B (zh) | 一种增强猪抗病毒性疫病的生物制剂 | |
| JP2022538935A (ja) | 遺伝子およびタンパク質の大きな運送物をヒト細胞に送達するための原核生物－真核生物ハイブリッドウイルスベクター | |
| CN114941013B (zh) | 重组间充质干细胞治疗糖尿病肺炎 | |
| JP2025515283A (ja) | ウイルスベクター用組成物及び方法 | |
| JPWO2022040204A5 (https=) | ||
| CN115975053A (zh) | 靶向新型冠状病毒的疫苗 | |
| CN114941012B (zh) | 重组间充质干细胞及其应用 | |
| CN121311235A (zh) | 炎症诱导型启动子 | |
| CN120519514A (zh) | 一种基于CRISPR-Cas13a的精准切割HIV病毒核酸的外泌体递送方法及其应用 |